Technology
Health
Biotechnology

Eidos Therapeutics

$29.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.38 (8.73%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EIDX and other stocks, options, ETFs, and crypto commission-free!

About

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. Read More The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

Employees
24
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.09B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
163.24K
High Today
$29.83
Low Today
$27.23
Open Price
$27.51
Volume
91.54K
52 Week High
$29.83
52 Week Low
$8.89

Collections

Technology
Health
Biotechnology
Top Movers
Therapy
2018 IPO
US
North America

News

Yahoo FinanceMay 10

Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. ?

62
Associated PressApr 30

Research Report Identifies National General, Eidos Therapeutics, Auris Medical Holding AG, and Realogy with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Press release content from Globe Newswire. The AP news staff was not involved in its creation. NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National General Holdings Corp (NASDAQ:NGHC), Eidos Therapeutics, Inc. (NASDAQ:EIDX), Auris Medical H...

28

Earnings

-$0.32
-$0.30
-$0.27
-$0.25
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.